Actinogen Medical Ltd has released a press release.
Prospectus - Non-renounceable Entitlement Offer
Filed with ASX ·
6ix hasn’t read this filing yet.
Actinogen Medical Limited on 6ix
Earlier from Actinogen Medical
- Actinogen announces capital raising of up to $8.9 million
- ACW March 2024 quarterly activity report & Appendix 4C
- ACW completes cognition & depression phase 2 trial enrolment
- First patient treated in ACW XanaMIA ph 2b Alzheimers trial
- Actinogen HY2024 financial results two key phase 2 trial
Later from Actinogen Medical
- Actinogen entitlement offer closed and oversubscribed
- ACW Oversubscribed $3.9 million entitlement offer completed
- Positive Xanamem biomarker trial published in Jnl Alz Dis
- ACW XanaCIDD depression trial results expected early August
- ACW June 2024 quarterly activity report & Appendix 4C
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical